Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Says USPTO Reverses Rejection of US Patent

Premium

Australia's Benitec said this week that the US Patent and Trademark Office has reversed its previous rejections of claims within the company's core US patent.

The patent, No. 6,573,099, covers gene-expression knockdown using DNA that transcribes double-stranded RNA. It fell under USPTO scrutiny as part of patent-infringement litigation the company initiated against now-defunct expressed RNAi shop Nucleonics, and certain claims within the intellectual property were rejected by the patent office (see GSN, 1/21/2010).

However, Benitec said that the rejection of all appealed claims in the patent has been reversed.

"It is therefore anticipated that the USPTO will soon issue a notice of intent to issue [an] ex parte re-examination certificate … which is analogous to the re-issuance of the patent certificate," the company said. "This notice would formally terminate the re-examination proceeding."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.